Australian boy, 10, accused of sexually assaulting Italian tourist
China Is Way Ahead in Green Energy. Here’s Why That’s Risky for the U.S.
What’s Best? Using a Credit Card or Cash on Vacation?
Formation : Apprivoiser Sa Colère Et Sa Nervosité : Savoir Redescendre En Pression !
Alex Verdugo loving life as Yankees’ cleanup hitter: ‘It’s a little bit humbling’
David Dominguez-Sola
Present address: Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
Carla Grandori
Present address: SEngine Precision Medicine, Bothell, Washington, 98021, USA
David Dominguez-Sola and Carol Y. Ying contributed equally to this work
Jean Gautier and Riccardo Dalla-Favera jointly supervised this work
Institute for Cancer Genetics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, 10032, USA
David Dominguez-Sola, Carol Y. Ying, Luca Ruggiero, Brenden Chen, Muyang Li, Wei Gu, Jean Gautier & Riccardo Dalla-Favera
Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
David Dominguez-Sola
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
David Dominguez-Sola
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, USA
Carla Grandori & Denise A. Galloway
Department of Pathology & Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA
Wei Gu
Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA
Wei Gu & Jean Gautier
Department of Genetics & Development, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA
Jean Gautier
Department of Immunology & Microbiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA
Riccardo Dalla-Favera
More News
How I fled bombed Aleppo to continue my career in science
Powerful ‘nanopore’ DNA sequencing method tackles proteins too
US funders to tighten oversight of controversial ‘gain-of-function’ research